Patients with ITP have multiple unmet needs
Current treatment goals in ITP are to stop active bleeding and reduce the risk of further bleeding. However, current treatment options have limitations, which can leave some needs unmet.1-4
Treatment classes such as corticosteroids, TPO-RAs, B-cell depleting agents, and SYK inhibitors:
May have a duration of platelet response that varies among patients2,4,5
May not address reduced QOL, fatigue, systemic inflammation, or TE risk that patients experience6-9
May be associated with unfavorable safety profiles, dosing regimens, routes of administration, and dietary restrictions2,5,8,10
Ongoing research aims to better address the multiple dimensions of ITP by targeting the underlying pathophysiology of the disease4,10
“I worry about my treatment failing at some point. I worry about the long-term health effects of the drugs that I’m taking.”
Tracey, real patient living with ITP
SYK, spleen tyrosine kinase.
1. Bussel J, Arnold DM, Grossbard E, et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials. Am J Hematol. 2018;93(7):921-930. 2. Cooper N, Ghanima W. Immune thrombocytopenia. N Engl J Med. 2019;381(10):945-955. 3. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386-2393. 4. Audia S, Bonnotte B. Emerging therapies in immune thrombocytopenia. J Clin Med. 2021;10(5):1004. 5. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-3866. 6. Cooper N, Kruse A, Kruse C, et al. Immune thrombocytopenia (ITP) World Impact Survey (I-WISh): impact of ITP on health-related quality of life. Am J Hematol. 2021;96(2):199-207. 7. Cooper N, Kruse A, Kruse C, et al. Immune thrombocytopenia (ITP) World Impact Survey (iWISh): patient and physician perceptions of diagnosis, signs and symptoms, and treatment. Am J Hematol. 2021;96(2):188-198. 8. Saldanha A, Colella MP, Villaça PR, Thachil J, Orsi FA. The immune thrombocytopenia paradox: should we be concerned about thrombosis in ITP? Thromb Res. 2024;241:109109. 9. Hill QA, Newland AC. Fatigue in immune thrombocytopenia. Br J Haematol. 2015;170(2):141-149. 10. Mingot-Castellano ME, Bastida JM, Caballero-Navarro G, et al. Novel therapies to address unmet needs in ITP. Pharmaceuticals (Basel). 2022;15(7):779.